ULIXERTINIB | ULIXERTINIB : Inhibitor of MAPK1, MAPK3
RATINGS:
Cellular Use: (0 reviews)

In Model Organisms: (0 reviews)
Control Compounds

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
MAPK1
  • IC50:140 nM (pRSK)
  • EC50:180 nM
MAPK3
    Inhibitor
    up to 1 uM

    Selectivity

    In Vitro Selectivity Assessment
    Selectivity Assessment Description:
    BVD-523 demonstrated ERK1/2 kinase selectivity based on biochemical counter-screens against 75 kinas ...

    Potency
    Cellular
    In Vitro

    MAPK1

    Mode of Action: Inhibitor

    Structure-Activity-Relationship data available? No

    DOI Reference: 10.1021/acs.jmedchem.5b00466

    MAPK3

    Mode of Action: Inhibitor

    Structure-Activity-Relationship data available? No

    DOI Reference: 10.1021/acs.jmedchem.5b00466

    In Vivo Validations

    Mouse
    Dose: 1 mg/Kg
    Route of delivery: Intravenous
    Plasma half life: 1.16 h
    Systemic clearance: 7.90 mL/min/kg
    Area Under the Curve:: 2109 ng*h/mL
    Volume of Distribution at Steady-State: 0.79 L/kg

    DOI Reference: 10.1016/j.jpba.2016.03.036

    Dose: 10 mg/Kg
    Route of delivery: Oral
    Plasma half life: 2.74 h
    Cmax: 8104 ng/mL
    Tmax: 0.5 h
    Area Under the Curve:: 23425 ng*h/mL
    Bioavailability: 100%

    DOI Reference: 10.1016/j.jpba.2016.03.036

    Orthogonal Probes def

    SCH772984

    Chemical Information

    Molecular Formula C21H22Cl2N4O2
    SMILEs CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1
    InChI InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
    Molecular weight 432.11 Da
    AlogP 4.667200000000003
    HBond acceptors 6
    HBond donors 4
    Atoms 51

    References

    Cross References

    Vendors

    Note: This is not an exhaustive list and does not indicate endorsement by the portal.

    Expert Reviews


    No SERP comments found for ULIXERTINIB

    Probe ULIXERTINIB is in the process of SERP review.

    Please continue to check back for new reviews and commentary.